Risk analysis by FMEA as an element of analytical validation.
暂无分享,去创建一个
D M Barends | D de Kaste | D. Barends | M. T. Oldenhof | M. Vredenbregt | M. Nauta | M T Oldenhof | J F van Leeuwen | M J Nauta | Y M C F Odekerken-Rombouts | M J Vredenbregt | D. de Kaste | J. F. van Leeuwen | Y. M. C. F. Odekerken-Rombouts | Y. Odekerken-Rombouts
[1] Mario Capunzo,et al. A FMEA clinical laboratory case study: how to make problems and improvements measurable. , 2004, Clinical leadership & management review : the journal of CLMA.
[2] James K. Drennen,et al. Risk Analysis for near Infrared Method Development , 2004 .
[3] Y Vander Heyden,et al. Improving method capability of a drug substance HPLC assay. , 2006, Journal of pharmaceutical and biomedical analysis.
[4] Jan S Krouwer,et al. An improved failure mode effects analysis for hospitals. , 2004, Archives of pathology & laboratory medicine.
[5] R G Kieffer,et al. Validation and the human element. , 1998, PDA journal of pharmaceutical science and technology.